Skip to content

UroGen Pharma URGN Free cash flow margin

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
24.6%-2.9pp
Pfizer logo
PfizerPFE
18%+8.8pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.5%-4.3pp
Merck & Co. logo
Merck & Co.MRK
21.5%-5.2pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-212%-95.8pp
CG Oncology logo
CG OncologyCGON
-3,163.8%-1,351pp

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

Based on trailing twelve months.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's free cash flow margin?
UroGen Pharma (URGN) reported free cash flow margin of -118.2% in Q1 2026.
How has UroGen Pharma's free cash flow margin changed year-over-year?
UroGen Pharma's free cash flow margin decreased by 1.1% year-over-year, from -116.9% to -118.2%.
What is the long-term trend for UroGen Pharma's free cash flow margin?
Over 5 years (2020 to 2025), UroGen Pharma's free cash flow margin has grown at a -30.4% compound annual growth rate (CAGR), from -907.7% to -148.2%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.